Seysara Shortage: What Providers and Prescribers Need to Know in 2026

Dermatologists and other prescribers increasingly report that patients are struggling to fill Seysara (sarecycline) prescriptions at standard retail pharmacies. While Seysara is not on the FDA Drug Shortage Database, its structural availability challenges create real barriers to access that prescribers need to understand and plan for. This guide summarizes what's happening and how to respond clinically.

Is Seysara Actually in Shortage?

Technically, no — Seysara is not listed on the FDA's formal shortage database as of 2026. Almirall continues to manufacture and distribute the drug. However, many patients and prescribers are experiencing de facto access problems that functionally resemble a shortage:

Retail pharmacies in many geographic areas do not routinely stock Seysara in any dose strength

Pharmacies that do stock Seysara may carry only one or two of the three dose strengths (60 mg, 100 mg, 150 mg)

Insurance non-coverage and prior authorization requirements reduce prescription volume, which further reduces pharmacy stocking incentives

The absence of a generic equivalent keeps retail pricing above $1,100/month cash pay, limiting self-pay access

Clinical Profile Recap: Why Prescribers Choose Seysara

Seysara (sarecycline) received FDA approval in October 2018 as the first oral antibiotic specifically developed for acne in over 40 years. It offers several clinically relevant advantages:

Narrow spectrum: Primarily targets Cutibacterium acnes with limited activity against gram-negative enteric flora, potentially reducing microbiome disruption compared to doxycycline and minocycline

Low resistance propensity: Spontaneous mutation frequencies of 10^-10 at 4-8x MIC — FDA-approved label describes low propensity for antibiotic resistance

Favorable tolerability: Most common adverse reaction is nausea (3.1% vs 2.0% placebo). Low rates of GI, vestibular, and phototoxic side effects compared to other tetracyclines

Pediatric approval: Indicated for patients 9 years and older, with weight-based dosing (60 mg, 100 mg, 150 mg once daily)

Efficacy: Studied in over 2,000 patients across three controlled clinical trials; significant reduction in inflammatory lesions at Week 12

Key Drug Interactions and Contraindications to Counsel

When prescribing Seysara, ensure patients are aware of the following:

Oral retinoids (isotretinoin, acitretin, tretinoin, bexarotene): Contraindicated — significantly increases risk of pseudotumor cerebri/intracranial hypertension

Antacids, calcium, magnesium, iron: Impair absorption — separate by 2 hours before or 6 hours after Seysara (4 hours for iron)

Digoxin: Sarecycline is a P-gp inhibitor; coadministration increased digoxin Cmax by 26% — monitor for digoxin toxicity

Penicillins: Tetracyclines may antagonize the bactericidal activity of penicillin-class antibiotics

Pregnancy: Contraindicated — can cause fetal harm including skeletal malformations and tooth discoloration. Discontinue immediately if pregnancy occurs.

Clinical Alternatives When Seysara Is Unavailable

When patients cannot access Seysara, the following alternatives are clinically appropriate for non-nodular moderate to severe inflammatory acne:

Doxycycline (generic): AAD strong recommendation; 100 mg once or twice daily; widely available; much lower cost. Higher photosensitivity risk. First-line when cost and access are priorities.

Minocycline (generic): Conditional AAD recommendation; 100 mg daily. Higher vestibular side effect risk (vertigo, dizziness); pigmentation risk with long-term use; rare autoimmune reactions.

Topical combination therapy: Clindamycin + benzoyl peroxide combinations (always use BPO to prevent resistance); appropriate for mild to moderate cases or as step-down after oral antibiotic response.

Helping Patients Navigate Pharmacy Access

When patients are struggling to locate Seysara at pharmacies, directing them to medfinder can save them significant time and frustration. medfinder calls pharmacies on the patient's behalf and texts them results — helping identify which local pharmacies have their specific dose strength in stock without the patient needing to call each location themselves.

Additionally, Almirall's specialty pharmacy network and the Almirall Advantage savings program can coordinate access and home delivery for commercially insured patients, sometimes at as little as $35/prescription with a copay card.

Bottom Line for Prescribers

Seysara remains a valuable clinical option for moderate to severe inflammatory acne with a favorable safety and resistance profile. Prescribers should proactively counsel patients about potential pharmacy access challenges, point them to the manufacturer savings program, and have a documented alternative plan ready. Establishing a preferred pharmacy relationship for Seysara within your practice workflow can reduce patient frustration and improve medication adherence.